Acorda Therapeutics, Inc., based in New York, confirmed the latest launch made by Esteve Pharmaceuticals, S.A. in Spain, a press release reported.
“Today’s announcement is great news for people in Spain who are living with Parkinson’s and suffer from OFF periods. Esteve is a leader in commercializing central nervous system therapeutics in Spain. They will be educating neurologists about providing patients with the ability to treat their OFF periods on-demand with INBRIJA,” said Ron Cohen, M.D., president and CEO of Acorda Therapeutics.
The new INBRIJA 33 mg is used for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease.
Under the terms of its deal with Esteve, Acorda will be granted a double-digit percent of INBRIJA’s selling price in Spain in exchange for the supply of the product.
The product became available in Spain to help those suffering from the chronic and progressive neurological disease, which is said to affect 160,000 people locally, according to data from the White Paper on Parkinson's in Spain. Approximately 10,000 new cases are reported each year, the Spanish Society of Neurology reported.
The launch follows the introduction of INBRIJA in Germany last year, and Acorda’s deal with Biopas Laboratories to commercialize INBRIJA in nine large Latin American markets, including Mexico and Brazil. The company confirmed various other talks of expansion in the works.